{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:26:11Z","timestamp":1769833571206,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10620-021-06843-4","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T08:04:06Z","timestamp":1612425846000},"page":"329-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC"],"prefix":"10.1007","volume":"67","author":[{"given":"Joon Yeul","family":"Nam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Bin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo-Cheol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Wook","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"6843_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends\u2014an update. Cancer Epidemiol Prev Biomarkers 2016;25:16\u201327","journal-title":"Cancer Epidemiol Prev Biomarkers"},{"key":"6843_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000444394","volume":"90","author":"BI Carr","year":"2016","unstructured":"Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90:215\u2013220","journal-title":"Oncology"},{"key":"6843_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00229.x","volume-title":"Natural history of untreated nonsurgical hepatocellular carcinoma","author":"YP Yeung","year":"2005","unstructured":"Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. LWW: City; 2005."},{"key":"6843_CR4","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1002\/hep.23944","volume":"52","author":"P Hilgard","year":"2010","unstructured":"Hilgard P, Hamami M, Fouly AE et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741\u20131749","journal-title":"Hepatology"},{"key":"6843_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/hep.24451","volume":"54","author":"B Sangro","year":"2011","unstructured":"Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868\u2013878","journal-title":"Hepatology"},{"key":"6843_CR6","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jhep.2005.12.015","volume":"44","author":"U Cillo","year":"2006","unstructured":"Cillo U, Vitale A, Grigoletto F et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723\u2013731","journal-title":"J Hepatol"},{"key":"6843_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3350\/cmh.2017.0004","volume":"23","author":"H-C Kim","year":"2017","unstructured":"Kim H-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017;23:109","journal-title":"Clin Mol Hepatol"},{"key":"6843_CR8","doi-asserted-by":"crossref","unstructured":"Liver EAFTSOT. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"6843_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011;53:1020","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"6843_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358\u2013380","journal-title":"Hepatology"},{"key":"6843_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jvir.2015.12.752","volume":"27","author":"RC Gaba","year":"2016","unstructured":"Gaba RC, Lewandowski RJ, Hickey R et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Intervent Radiol JVIR 2016;27:457","journal-title":"J Vasc Intervent Radiol JVIR"},{"key":"6843_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jvir.2016.09.024","volume":"28","author":"SA Padia","year":"2017","unstructured":"Padia SA, Lewandowski RJ, Johnson GE et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol JVIR 2017;28:1","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"6843_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/jgh.13250","volume":"31","author":"A Hiraoka","year":"2016","unstructured":"Hiraoka A, Kumada T, Michitaka K et al. Usefulness of albumin\u2013bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:1031\u20131036","journal-title":"J Gastroenterol Hepatol"},{"key":"6843_CR14","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/annonc\/mdt247","volume":"24","author":"L Kadalayil","year":"2013","unstructured":"Kadalayil L, Benini R, Pallan L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24:2565\u20132570","journal-title":"Ann Oncol"},{"key":"6843_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-06975-2","volume":"20","author":"JY Nam","year":"2020","unstructured":"Nam JY, Choe AR, Sinn DH et al. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:1\u201314","journal-title":"BMC Cancer"},{"key":"6843_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/hepr.13048","volume":"48","author":"Y Yasui","year":"2018","unstructured":"Yasui Y, Tsuchiya K, Kurosaki M et al. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 2018;48:442\u2013450","journal-title":"Hepatol Res"},{"key":"6843_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1159\/000481315","volume":"6","author":"CE Costentin","year":"2017","unstructured":"Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AXJLC. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer 2017;6:360\u2013374","journal-title":"Liver Cancer"},{"key":"6843_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/liv.12637","volume":"35","author":"A El Fouly","year":"2015","unstructured":"El Fouly A, Ertle J, El Dorry A et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627\u2013635","journal-title":"Liver Int"},{"key":"6843_CR19","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","volume":"36","author":"LE Moreno-Luna","year":"2013","unstructured":"Moreno-Luna LE, Yang JD, Sanchez W et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Interv Radiol 2013;36:714\u2013723","journal-title":"Cardiovasc Interv Radiol"},{"key":"6843_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1007\/s00270-016-1426-y","volume":"39","author":"L Lobo","year":"2016","unstructured":"Lobo L, Yakoub D, Picado O et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Interv Radiol 2016;39:1580\u20131588","journal-title":"Cardiovasc Interv Radiol"},{"key":"6843_CR21","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","volume":"51","author":"L Strigari","year":"2010","unstructured":"Strigari L, Sciuto R, Rea S et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377\u20131385","journal-title":"J Nucl Med"},{"key":"6843_CR22","doi-asserted-by":"publisher","first-page":"e82225","DOI":"10.1371\/journal.pone.0082225","volume":"8","author":"Z Weng","year":"2013","unstructured":"Weng Z, Ertle J, Zheng S et al. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS One 2013;8:e82225","journal-title":"PLoS One"},{"key":"6843_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/MEG.0000000000001585","volume":"32","author":"JS Lee","year":"2020","unstructured":"Lee JS, Lee HA, Jeon MY et al. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. Eur J Gastroenterol Hepatol 2020;32:739\u2013747","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-06843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-06843-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-06843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:46:31Z","timestamp":1641584791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-06843-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["6843"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-06843-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"assertion":[{"value":"10 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that there is no conflict of financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}